151 related articles for article (PubMed ID: 36754935)
1. Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer.
Buehner TM; Liotta M; Potkul RK; Wagner RH; Savir-Baruch B
Mol Imaging Biol; 2024 Feb; 26(1):45-52. PubMed ID: 36754935
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM
J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619
[TBL] [Abstract][Full Text] [Related]
4. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
5. Detection of Additional Primary Neoplasms on
Parihar AS; Schmidt LR; Dehdashti F; Wahl RL
J Nucl Med; 2022 May; 63(5):713-719. PubMed ID: 34413144
[TBL] [Abstract][Full Text] [Related]
6. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
[TBL] [Abstract][Full Text] [Related]
7. Comparison of [
Stokke C; Nørgaard JN; Feiring Phillips H; Sherwani A; Nuruddin S; Connelly J; Schjesvold F; Revheim ME
Mol Imaging Biol; 2022 Oct; 24(5):842-851. PubMed ID: 35501622
[TBL] [Abstract][Full Text] [Related]
8.
Abiodun-Ojo OA; Akintayo AA; Akin-Akintayo OO; Tade FI; Nieh PT; Master VA; Alemozaffar M; Osunkoya AO; Goodman MM; Fei B; Schuster DM
J Nucl Med; 2019 Nov; 60(11):1531-1536. PubMed ID: 30954940
[TBL] [Abstract][Full Text] [Related]
9. A PET/MRI study towards finding the optimal [
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
[TBL] [Abstract][Full Text] [Related]
10. Characterizing and Mitigating Bladder Radioactivity on
Lovrec P; Schuster DM; Wagner RH; Gabriel M; Savir-Baruch B
J Nucl Med Technol; 2020 Mar; 48(1):24-29. PubMed ID: 31604898
[No Abstract] [Full Text] [Related]
11. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
Suzuki H; Jinnouchi S; Kaji Y; Kishida T; Kinoshita H; Yamaguchi S; Tobe T; Okamura T; Kawakita M; Furukawa J; Otaka A; Kakehi Y
Jpn J Clin Oncol; 2019 Sep; 49(9):803-811. PubMed ID: 31095314
[TBL] [Abstract][Full Text] [Related]
13.
Michaud L; Beattie BJ; Akhurst T; Dunphy M; Zanzonico P; Finn R; Mauguen A; Schöder H; Weber WA; Lassman AB; Blasberg R
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1353-1367. PubMed ID: 31418054
[TBL] [Abstract][Full Text] [Related]
14. Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer.
Sörensen J; Owenius R; Lax M; Johansson S
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):394-402. PubMed ID: 23208700
[TBL] [Abstract][Full Text] [Related]
15. Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer.
Baiomy A; Schellingerhout D; Chapin BF; Weinberg JS; Raza SM; Macapinlac H; Ravizzini G
Nucl Med Commun; 2021 Jul; 42(7):755-762. PubMed ID: 33741867
[TBL] [Abstract][Full Text] [Related]
16. Prospective Clinical Trial of
Ulaner GA; Goldman DA; Corben A; Lyashchenko SK; Gönen M; Lewis JS; Dickler M
J Nucl Med; 2017 Jul; 58(7):1037-1042. PubMed ID: 27856630
[No Abstract] [Full Text] [Related]
17. 18F-Fluciclovine PET/MRI in a Patient With Squamous Cell Carcinoma of the Uterine Cervix Correlated With 18F-FDG PET/CT.
Nguyen NC; Moon CH; Beriwal S
Clin Nucl Med; 2020 Oct; 45(10):802-804. PubMed ID: 32558719
[TBL] [Abstract][Full Text] [Related]
18. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
[TBL] [Abstract][Full Text] [Related]
19. Utility of
Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
[No Abstract] [Full Text] [Related]
20. 18F-Fluciclovine PET/CT: A Potential Imaging Biomarker for the Evaluation of Multiple Myeloma.
Marcus C; Schuster DM; Tajmir SH
Clin Nucl Med; 2022 Sep; 47(9):e613-e615. PubMed ID: 35930716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]